LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer (LIBIL)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02511288 |
Recruitment Status :
Recruiting
First Posted : July 30, 2015
Last Update Posted : October 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Carcinoma, Non-Small-Cell Lung |
Lung cancers are the first cause of death by cancer in the world. The majority of these patients are diagnosed at a late stage, non-eligible to a curative treatment. Due to tumoral genomic identification, it has been possible to classify NSCLC in molecular subtypes according to molecular abnormalities detection called "drivers" which can be targeted using an appropriate treatment. This change modifies the standard treatments from the very first line of treatment particularly for patients having an EGFR mutation or an ALK or ROS1 rearrangement, with a significant benefit of progression free survival. The French NCI (INCa) recommends to identify genomic alterations of a genes panel including EGFR, KRAS, BRAF, HER2, ALK and ROS1 as well as mutations in MET exon 14. However, all the patients who benefit from a targeted therapy develop resistance after a mean duration of 10-12 months after starting the treatment. In case of progression, the tumour genetic analysis through new biopsies, enables to identify these mechanisms and then to determine if the patient can benefit or not from a third generation molecule active on these mechanisms, and to have a better understanding of the disease evolution.
The detection of these alterations is routinely performed using tissular biopsies but in 10 to 20% of the cases, it is not possible.
The detection of these molecular abnormalities in the plasma, called " liquid biopsy " is a valuable non-invasive complementary approach for these patients. It is presently used in routine for detecting the EGFR mutations at diagnosis as well as for searching EGFR T790M mutation for resistant patients.
The liquid biopsies enable to detect circulating tumoral DNA.
Study Type : | Observational |
Estimated Enrollment : | 900 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Liquid Biopsies in Patients With Advanced Non-small Cell Lung Cancer |
Actual Study Start Date : | July 2015 |
Estimated Primary Completion Date : | March 2026 |
Estimated Study Completion Date : | December 2026 |
Group/Cohort |
---|
Cohort 1
Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis
|
Cohort 2
Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis
|
Cohort 3
Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)
|
- Identification of the genetic profile in advanced or metastatic NSCLC patients using liquid biopsies (circulating tumoral DNA) [ Time Frame: 5 years ]Technique: ddPCR + targeted NGF, whole exome sequencing
- Identification of genetic biomarkers (or molecular profiles) having a potential predictive value in the treatments response [ Time Frame: 5 years ]Techniques: ddPCR + targeted NGF, whole exome sequencing
- Detection of the ALK and ROS1 genes translocations in the circulating DNA [ Time Frame: 5 years ]Techniques: ddPCR + targeted NGF, whole exome sequencing
- Evaluation of the liquid biopsies role in the tumoral monitoring [ Time Frame: 5 years ]Correlation between mutated allelic fractions or expression's modification with the treatment response. Techniques: ddPCR + targeted NGF, whole exome sequencing
- Evaluation of genomic and transcriptomic factors detectable in the plasma, associated to the immunotherapy response [ Time Frame: 5 years ]Correlation between transcriptomic and genomic factors and response to immunotherapy. Techniques: ddPCR + targeted NGF, whole exome sequencing
- Evaluation of the spatial and temporal tumor heterogeneity under targeted therapy treatment [ Time Frame: 5 years ]Techniques: ddPCR + targeted NGF, whole exome sequencing
- Evaluation of the miRNAs' expression in plasma as an epigenetic factor associated to treatments response [ Time Frame: 5 years ]Correlation between miRNAS expression in plasma and treatment's efficacy. Techniques: miRNAs profiling using HTG technology
- Circulating tumoral cells isolation and analysis to determine the role of non-genomic and/or phenotypic factors in the treatments response. [ Time Frame: 5 years ]Single cell isolation technology
- Evaluation of the resistance mechanisms to targeted therapies [ Time Frame: 5 years ]Technique: ddPCR + targeted NGF, whole exome sequencing
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
COHORT 1
Inclusion Criteria:
- Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status
- Inclusion at the time of diagnostic
- Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
- Age ≥ 18 years
- Covered by a health insurance
- Signed consent
Exclusion Criteria:
- Patients treated before their liquid biopsy
COHORT 2 Inclusion criteria
- Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement.
- Inclusion at the time of diagnosis
- Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
- Age ≥ 18 years
- Covered by a health insurance
- Signed consent
COHORT 3 Inclusion criteria
- Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status.
- Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line)
- Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
- Age ≥ 18 years
- Covered by a health insurance
- Signed consent
Exclusion criteria
- Initiation of immunotherpy before their liquid biopsy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02511288
Contact: Pierre Saintigny, MD, PhD | pierre.saintigny@lyon.unicancer.fr |
France | |
Centre Hospitalier Annecy Genevois | Recruiting |
Annecy, France | |
Contact: Stéphane Hominal, MD +33 4.50.63.66.03 shominal@ch-annecygenevois.fr | |
CH Fleyriat | Recruiting |
Bourg-en-Bresse, France | |
Contact: Pascal Beynel, MD +33 4.74.45.40.30 pbeynel@ch-bourg01.fr | |
Hôpital Louis Pradel | Recruiting |
Bron, France, 69677 | |
Contact: Marylise Ginoux, MD +33 4.27.85.77.00 marylise.ginoux@chu-lyon.fr | |
CHU Grenoble Alpes | Recruiting |
Grenoble, France | |
Contact: Denis Moro-Sibilot, MD +33 4.76..76.87.08 smoro-sibilot@chu-grenoble.fr | |
Centre Léon Bérard | Recruiting |
Lyon, France, 69008 | |
Contact: Pierre Saintigny, MD-PhD +33 478782781 pierre.saintigny@lyon.unicancer.fr | |
CHRU de Saint-Etienne | Recruiting |
Saint-Priest-en-Jarez, France, 42270 | |
Contact: Sophie Bayle-Bleuez, MD Sophie.bayle@chu-st-etienne.fr | |
Institut de Cancérologie Lucien Neuwirth | Recruiting |
Saint-Priest-en-Jarez, France, 42270 | |
Contact: Pierre Fournel, MD +33 4.77.91.70.36 pierre.fournel@icloire.fr | |
Hôpital Nord Ouest | Recruiting |
Villefranche-sur-Saône, France, 69655 | |
Contact: Luc Odier, MD +33 4.74.09.27.23 lodier@lhopitalnordouest.fr |
Study Director: | Pierre Saintigny, MD, PhD | pierre.saintigny@lyon.unicancer.fr |
Responsible Party: | Centre Leon Berard |
ClinicalTrials.gov Identifier: | NCT02511288 |
Other Study ID Numbers: |
ET15-076 LIBIL |
First Posted: | July 30, 2015 Key Record Dates |
Last Update Posted: | October 8, 2021 |
Last Verified: | October 2021 |
Hematologic test Liquid biopsy |
Carcinoma, Non-Small-Cell Lung Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms |
Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |